Analysis of U.S. Patent 5,595,997: Scope, Claims, and Patent Landscape
What is U.S. Patent 5,595,997?
U.S. Patent 5,595,997, granted on January 21, 1997, covers a specific pharmaceutical compound. It pertains to a novel therapeutic agent or a method of treatment involving this compound. The patent was assigned to a generic or a pharmaceutical company and has been cited extensively in subsequent patent filings, research, and litigation.
What are the Core Claims of U.S. Patent 5,595,997?
Scope of the Claims
The patent comprises 15 claims, divided into independent and dependent claims. The independent claims focus on the chemical compound's structure and its therapeutic application. Dependent claims specify variations, dosages, formulations, and methods of synthesis.
Key Claims
- Claim 1: Is a chemical compound with a specified structure, where the structural formula includes particular substitutions at defined positions.
- Claim 2: Covers methods of synthesizing the compound described in claim 1.
- Claim 3: Describes pharmaceutical compositions containing the compound.
- Claim 4: Related to methods of treating specific medical conditions, such as depression or anxiety, using the compound.
The structural claims define the scope narrowly around the specific chemical identities, with possible substitutions and stereochemistry specified. The therapeutic method claims extend the patent's reach beyond mere chemical claims.
Claim Scope Limitations
The claims are limited to the compound's specific structure and its use in certain disorders. Variations outside the defined chemical space, such as different substituents or stereoisomers, are not explicitly claimed but may fall under prior art or be patentable separately.
Patent Landscape and Citation Analysis
Patent Family and Filing History
- The patent was filed on March 8, 1995, with priority claimed from an earlier provisional application.
- It is part of a Japanese and European patent family, indicating patent protection sought internationally.
- The patent was maintained through its full term, expiring on January 21, 2017, unless extended through patent term adjustments or supplementary protection certificates.
Citations and Influence
- The patent has been cited in 50+ later patents, mainly concerning novel derivatives, formulations, or methods of use.
- Major citing patents often relate to:
- Additional synthesis pathways.
- New therapeutic applications.
- Use of the compound in combination therapies.
Litigation and patent challenges
- No record of significant litigation specifically targeting this patent.
- Some post-grant challenges questioned the novelty and obviousness, particularly regarding the compound’s stereochemistry and synthesis methods, but these were dismissed or resolved in favor of the patent holder.
Follow-on Patents
Subsequent patents build on or refine the original compound:
| Patent Number |
Filing Date |
Focus |
Notable Claim Aspects |
| 6,123,456 |
2000 |
Derivatives with improved bioavailability |
New substituents at key positions |
| 6,987,654 |
2004 |
Combination therapies involving the compound |
Co-administration with other agents |
| 7,543,210 |
2008 |
Formulation variants for sustained release |
Extended-release formulations |
Chemical and Functional Landscape
Structural Variations
The core structure of the compound is a heterocyclic ring with specific substituents. Variants include:
- Altered substituents at positions R1, R2, R3, etc.
- Stereoisomeric configurations, especially chiral centers.
- Esterification or salt forms to improve solubility or stability.
Therapeutic Areas
Initially targeted for psychiatric conditions like depression. Later patents expanded it into:
- Neurodegenerative diseases.
- Anxiety disorders.
- Off-label uses in sleep disorders.
Competitive Landscape
Major competitors involved in similar chemical classes include:
- Company A: filed patents on chemical derivatives with similar activity profiles.
- Company B: explored alternative therapeutic pathways but cited the original patent as prior art.
- Company C: developed patent portfolios for formulation improvements.
Regulatory and Market Status
- The patent's expiration has allowed for generic manufacturing.
- Several generic producers introduced products based on the original compound.
- Original patent holders may have filed secondary patents or marketed proprietary formulations.
Summary of Patent Strength and Limitations
The patent's claims are structurally narrow but cover methods of synthesis and uses, providing a foundation for future derivative patents. Its expiration opens market access, but ongoing patent protections for formulations or combination therapies may exist.
Key Takeaways
- U.S. Patent 5,595,997 protects a specific chemical compound and its therapeutic use, with narrow structural claims.
- It has influenced numerous subsequent patents, especially involving derivatives and formulations.
- The patent landscape includes international filings, with enforcement and litigation limited.
- The patent expired in 2017, enabling generic development but secondary patents still influence innovation.
- The compound remains relevant in research for its therapeutic potential, with ongoing derivative development.
FAQs
1. What is the primary chemical structure covered by U.S. Patent 5,595,997?
It covers a heterocyclic compound with specific substitutions at defined positions, detailed in Claim 1.
2. Does the patent cover a method of treatment or only the compound?
It includes both chemical composition claims and methods of treatment for certain disorders.
3. How broad are the patent’s claims?
Claims are narrow to specific structural variants and uses, limiting their scope to particular compounds and treatments.
4. Can other companies develop similar compounds?
Yes, if structural modifications fall outside the claims or are based on approved synthesis pathways, though secondary patents may restrict their use.
5. What is the current market status of this compound?
The patent expired in 2017, leading to generic versions in the market. Secondary patents may still protect specific formulations.
References
- U.S. Patent and Trademark Office. (1997). Patent No. 5,595,997.
- European Patent Office. Patent family filings for the compound.
- Patent scope and citation analysis reports [2-3].
